ESMO 2019 Archives - Medical Conferences

Home > Oncology > ESMO 2019

Read the full Report (pdf)

European Society for Medical Oncology

27 September – 01 October 2019, Barcelona, Spain

Featured articles

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Esch, Luxembourg

Conference

ESMO 2019

26 November 2019 23:32

Interview with ESMO President Prof. Josep Tabernero

Expert

Prof. Josep Tabernero, Vall d’Hebron University Hospital, Barcelona, Spain

Conference

ESMO 2019

26 November 2019 13:32

Online First

Breast Cancer

Triple negative breast cancer gets positive news: KEYNOTE-522 interim results

Presented By

Prof. Peter Schmid, Queen Mary University of London, UK

Trial

Phase 3, KEYNOTE-522

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:12

CDK4/6 inhibitors change landscape of breast cancer treatment: 2 studies

Presented By

Prof. Dennis Slamon, Prof. George Sledge, Prof. Nadia Harbeck

Trial

Monaleesa-3, Monarch 2

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 22:03

Veliparib-chemo combo prolongs survival without disease progression in some advanced breast cancer patients

Presented By

Veronique Diéras, Centre Eugène Marquis, Rennes, France

Trial

Phase 3, BROCADE 3

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:04

Lung Cancer

Improved response rates without survival benefit with pembrolizumab in pretreated mesothelioma

Presented By

Dr Sanjay Popat, Royal Marsden Hospital NHS Foundation Trust, UK

Trial

PROMISE-meso

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:04

Frontline ipilimumab/nivolumab improves OS in advanced NCLSC

Presented By

Prof. Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Trial

Phase 3, CheckMate-227

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 22:05

First-line osimertinib significantly lengthens OS in NSCLC

Presented By

Prof. Suresh Ramalingam, Emory University, Atlanta, USA

Trial

Phase 3, FLAURA

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 21:05

Liquid biopsy to decide the best treatment for NSCLC

Presented By

Dr Shirish Gadgeel, University of Michigan, USA

Trial

Phase 2, BFAST

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:05

Melanoma

Long-term data from CheckMate 067

Presented By

Prof. James Larkin, Royal Marsden NHS Foundation Trust, London, UK

Trial

Phase 3, CheckMate 067

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:06

Adjuvant nivolumab provides benefit

Presented By

Prof. Jeffrey S. Weber, NYU Langone Medical Center, New York City, USA

Trial

Phase 3, CheckMate 238

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 22:15

Nivolumab+ipilimumab superior to monotherapy for melanoma brain metastases

Presented By

Prof. Georgina Long, Melanoma Institute Australia, Sydney, Australia

Trial

ABC

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:15

GI Cancers

Preoperative chemotherapy for colon cancer

Presented By

Prof. Dion Morton, University of Birmingham, UK

Trial

FOxTROT, phase 2/3

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:20

Nivolumab improves OS in advanced oesophageal cancer

Presented By

Prof. Byoung Chul Cho, Yonsei University College of Medicine, South Korea

Trial

Phase 3, ATTRACTION-3

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 22:19

Liquid biopsy identifies relapse in patients with colorectal cancer after surgery

Presented By

Prof. Julien Taieb, Hopital European Georges Pompidou, France

Trial

Phase 3, IDEA-FRANCE

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 21:17

In hepatocellular carcinoma, CheckMate 459 misses OS endpoint, but some interesting trends emerge

Presented By

Dr Thomas Yau, University of Hong Kong, China

Trial

Phase 3, CheckMate 459

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 20:21

Heavily pre-treated GIST: ripretinib improves PFS

Presented By

Prof. Margaret von Mehren, Fox Chase Cancer Center, USA

Trial

Phase 3, INVICTUS

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 19:21

FGFR2+ cholangiocarcinoma: pemigatinib active as second-line treatment

Presented By

Prof. Antoine Hollebecque, Gustave Roussy Cancer Center, France

Trial

Phase 2, FIGHT-202

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 18:21

IDH1+ cholangiocarcinoma: phase 3 results show improved PFS

Presented By

Dr Ghassan Abou-Alfa, Memorial Sloan-Kettering Cancer Center, New York, USA

Trial

Phase 3, ClarIDHy

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 17:22

Advanced colorectal cancer and BRAF mutations: triplet combination improves survival

Presented By

Prof. Scott Kopetz, MD Anderson Cancer Center, Houston, USA

Trial

Phase 3, BEACON CRC

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:22

Genitourinary Cancers

25% reduction in the risk of death in patients with nmCRPC treated with apalutamide

Presented By

Prof. Matthew Smith, Massachusetts General Hospital, Boston, USA

Trial

Phase 3, SPARTAN

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:23

Enfortumab vedotin and pembrolizumab in advanced bladder cancer: initial results

Presented By

Prof. Christopher Hoimes, Case Comprehensive Cancer Center, Cleveland, USA

Trial

Phase 1, EV-103

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 22:23

PARP inhibition in selected patients slows progression on advanced prostate cancer

Presented By

Prof. Maha Hussain, Northwestern University, Chicago, USA

Trial

Phase 3, PROfound

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 21:24

PFS extension with immunotherapy + chemotherapy in urothelial cancer

Presented By

Dr Enrique Grande, MD Anderson Cancer Centre Madrid, Spain

Trial

IMvigor130

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 21:24

Third-line in mCRPC: CARD trial

Presented By

Prof. Ronald De Wit, Erasmus University Rotterdam, the Netherlands

Trial

CARD

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 20:24

Prostate cancer: spare radiotherapy after surgery

Presented By

Prof. Chris Parker, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UK

Trial

RADICALS-RT

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 18:24

Novel mode of action for kidney cancer treatment

Presented By

Prof. Eric Jonasch, MD Anderson Cancer Center, Houston, USA

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:24

Gynaecological Cancers

Ovarian cancer patients benefit from combined maintenance therapy

Presented By

Prof. Isabelle Ray-Coquard, Université Claude Bernard, Lyon, France

Trial

Phase 3, PAOLA-1/ENGOT-ov25

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:25

Combination of PARP inhibition plus chemotherapy in ovarian cancer

Presented By

Robert Coleman, University of Texas, MD Anderson Cancer Center, Houston, USA

Trial

Phase 3, VELIA

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 22:26

PFS benefit with niraparib as first-line maintenance in ovarian cancer

Principal Investigator

Prof. Antonio González Martín, Clinica Universidad de Navarra, Spain

Trial

Phase 3, PRIMA/ENGOT-OV26/GOG-3012

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:26

CNS Tumours

Ceritinib in ALK+ NSCLC brain metastases

Presented By

Dr Laura Quan Man Chow, University of Texas at Austin, USA

Trial

Phase 2, ASCEND-7

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:28

Adding bevacizumab to temozolomide-based therapy in neuroblastoma

Trial

Phase 2, BEACON-Neuroblastoma

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:29

Solid Tumours/Pan-Tumour Data

Mixed data: AMG 510 in tumours with KRASG12C

Presented By

Prof. Ramaswamy Govindan, Washington University, St Louis, USA

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:30

DNA profiling of carcinoma of unknown primary should inform treatment

Presented By

Prof. Karim Fizazi, University of Paris Sud, France

Trial

GEFCAPI 04, CUPISCO

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 22:30

Larotrectinib: safe and effective in TRK fusion-positive tumours

Presented By

Dr David Hyman, Memorial Sloan Kettering Cancer Center, New York, USA

Trial

SCOUT, NAVIGATE

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:30

Featured articles

CONTENTS

Online First

Breast Cancer

Lung Cancer

Melanoma

GI Cancers

Genitourinary Cancers

Gynaecological Cancers

CNS Tumours

Solid Tumours/Pan-Tumour Data